Drug
Povorcitinib
Povorcitinib: highest development phase Phase 3, developed by Incyte. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| Povorcitinib NCT06113445 | Phase 3 | NonSegmental Vitiligo |
| Povorcitinib NCT05620836 | Phase 3 | Hidradenitis Suppurativa (HS) |
| povorcitinib NCT06855498 | Phase 3 | Hidradenitis Suppurativa (HS) |
| Povorcitinib NCT06380205 | Phase 1 | Healthy Participants |
Latest
No recent events.
Follow Povorcitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.